Study of BEBT-908 in Subjects With Advanced Hematological Tumors
Status:
Completed
Trial end date:
2019-03-08
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the safety and tolerance of BEBT-908 for injection
in the treatment of recurrent refractory malignant lymphoma, multiple myeloma and chronic
lymphoblastic leukemia, and to obtain the pharmacokinetic data and preliminary efficacy of
BEBT-908 for injection, and to explore the relationship between the safety and efficacy of
BEBT-908 for injection and related biomarkers.